Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 533 articles:
HTML format
Text format



Single Articles


    June 2018
  1. BROWN DA, Himes BT, Kerezoudis P, Chilinda-Salter YM, et al
    Insurance Correlates with Improved Access to Care and Outcome Among Glioblastoma Patients.
    Neuro Oncol. 2018 Jun 11. pii: 5035412. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. KUNZ M, Albert NL, Unterrainer M, la Fougere C, et al
    Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
    Neuro Oncol. 2018 Jun 9. pii: 5035376. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. FALK DELGADO A, De Luca F, van Westen D, Falk Delgado A, et al
    Arterial Spin Labeling MR imaging for differentiation between high and low grade glioma - a meta-analysis.
    Neuro Oncol. 2018 Jun 2. pii: 5032325. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. LOMBARDI G, Della Puppa A, Gardiman MP, Rossi S, et al
    Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma.
    Neuro Oncol. 2018 Jun 2. pii: 5032324. doi: 10.1093.
    PubMed     Text format    


    May 2018
  5. ZHANG L, He L, Lugano R, Roodakker K, et al
    IDH-mutation Status is Associated with Distinct Vascular Gene Expression Signatures in Lower Grade Gliomas.
    Neuro Oncol. 2018 May 29. pii: 5018656. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. DASGUPTA A, Gupta T, Pungavkar S, Shirsat N, et al
    Nomograms based on Pre-operative Multi-parametric Magnetic Resonance Imaging for Prediction of Molecular Subgrouping in Medulloblastoma: Results from a Radiogenomics Study of 111 Patients.
    Neuro Oncol. 2018 May 29. pii: 5018966. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. JOSEPH SK, Samaha H, Bielamowicz K, Ahmed N, et al
    Invited Response to the Comment by Caruso and Heimberger on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma" by Bielamowicz et al.
    Neuro Oncol. 2018 May 19. pii: 4999739. doi: 10.1093.
    PubMed     Text format    


  8. BROWN NF, Williams M, Arkenau HT, Fleming RA, et al
    A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
    Neuro Oncol. 2018 May 17. pii: 4998845. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. GILLESPIE S, Monje M
    An Active Role for Neurons in Glioma Progression: Making Sense of Scherer's Structures.
    Neuro Oncol. 2018 May 17. pii: 4998849. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. GEURTS M, van den Bent MJ
    Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?
    Neuro Oncol. 2018 May 15. pii: 4996074. doi: 10.1093.
    PubMed     Text format    


  11. VAN DEN BOSSCHE WBL, Kleijn A, Teunissen CE, Voerman JSA, et al
    Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    Neuro Oncol. 2018 May 15. pii: 4996453. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. CLAUS EB, Cornish AJ, Broderick P, Schildkraut JM, et al
    Genome-wide association analysis identifies a meningioma risk locus at 11p15.5.
    Neuro Oncol. 2018 May 12. pii: 4995586. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. CLOUGHESY TF, Landolfi J, Vogelbaum MA, Ostertag D, et al
    Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC.
    Neuro Oncol. 2018 May 12. pii: 4995454. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. PUDELKO L, Edwards S, Balan M, Nyqvist D, et al
    An orthotopic glioblastoma animal model suitable for high-throughput screenings.
    Neuro Oncol. 2018 May 10. pii: 4994699. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. ZACHARIAH M, Oliveira-Costa JP, Carter B, Stott SL, et al
    Blood-Based Biomarkers for the Diagnosis and Monitoring of Gliomas.
    Neuro Oncol. 2018 May 9. pii: 4994194. doi: 10.1093.
    PubMed     Text format    


  16. GUPTA N, Goumnerova LC, Manley P, Chi SN, et al
    Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma.
    Neuro Oncol. 2018 May 5. pii: 4993208. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. KARACHI A, Dastmalchi F, Mitchell D, Rahman M, et al
    Temozolomide for Immunomodulation in the Treatment of Glioblastoma.
    Neuro Oncol. 2018 May 4. pii: 4992672. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. PAECH D, Windschuh J, Oberhollenzer J, Dreher C, et al
    Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multi-pool CEST MRI at 7.0 Tesla.
    Neuro Oncol. 2018 May 4. pii: 4992691. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  19. STADLBAUER A, Zimmermann M, Doerfler A, Oberndorfer S, et al
    Intratumoral Heterogeneity of Oxygen Metabolism and Neovascularization Uncovers Two Survival Relevant Subgroups of IDH1 Wild-type Glioblastoma.
    Neuro Oncol. 2018 Apr 28. pii: 4989834. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. ELLINGSON BM, Abrey LE, Garcia J, Chinot O, et al
    Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo.
    Neuro Oncol. 2018 Apr 20. pii: 4979515. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. HERSH DS, Harder BG, Roos A, Peng S, et al
    The TNF Receptor Family Member Fn14 is Highly Expressed in Recurrent Glioblastoma (GBM) and in GBM Patient-Derived Xenografts With Acquired Temozolomide Resistance.
    Neuro Oncol. 2018 Apr 20. pii: 4979510. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. DU Z, Brewster R, Merrill PH, Chmielecki J, et al
    Meningioma transcription factors link cell lineage with systemic metabolic cues.
    Neuro Oncol. 2018 Apr 12. pii: 4969420. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. KOGA T, Li B, Figueroa JM, Ren B, et al
    Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
    Neuro Oncol. 2018 Apr 12. pii: 4969527. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. CARUSO H, Heimberger AB
    Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma".
    Neuro Oncol. 2018 Apr 10. pii: 4965825. doi: 10.1093.
    PubMed     Text format    


  25. LINNINGER A, Hartung GA, Liu BP, Mirkov S, et al
    Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
    Neuro Oncol. 2018 Apr 5. pii: 4962158. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. ELLINGSON BM, Abrey LE, Nelson SJ, Kaufmann TJ, et al
    Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
    Neuro Oncol. 2018 Apr 5. pii: 4962189. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. ELLINGSON BM, Aftab DT, Schwab GM, Hessel C, et al
    Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Neuro Oncol. 2018 Apr 5. pii: 4962211. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. ALEXANDER BM, Cloughesy TF
    Platform trials arrive on time for glioblastoma.
    Neuro Oncol. 2018 Apr 2. pii: 4958219. doi: 10.1093.
    PubMed     Text format    


    March 2018
  29. AKBARI H, Bakas S, Pisapia JM, Nasrallah MP, et al
    In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
    Neuro Oncol. 2018 Mar 30. pii: 4956862. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. BABAK S, Mason WP
    mTOR inhibition in glioblastoma: requiem for a dream?
    Neuro Oncol. 2018 Mar 28. pii: 4955983. doi: 10.1093.
    PubMed     Text format    


  31. NASSIRI F, Aldape K, Zadeh G
    The multiforme of glioblastoma.
    Neuro Oncol. 2018;20:437-438.
    PubMed     Text format    


  32. BOXERMAN JL, Zhang Z, Safriel Y, Rogg JM, et al
    Prognostic Value of Contrast Enhancement and FLAIR for Survival in Newly Diagnosed Glioblastoma Treated With and Without Bevacizumab: Results from ACRIN 6686.
    Neuro Oncol. 2018 Mar 26. pii: 4953723. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. BROEN MPG, Smits M, Wijnenga MMJ, Dubbink HJ, et al
    The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
    Neuro Oncol. 2018 Mar 26. pii: 4953716. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. SAADEH FS, Melamed EF, Rea ND, Krieger MD, et al
    Seizure outcomes of supratentorial brain tumor resection in pediatric patients.
    Neuro Oncol. 2018 Mar 20. pii: 4944459. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. PEDROSA R, Mustafa DA, Soffietti R, Kros JM, et al
    Breast cancer brain metastasis: molecular mechanisms and directions for treatment.
    Neuro Oncol. 2018 Mar 16. pii: 4939604. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. HE J, Zhao Y, Zhao E, Wang X, et al
    Cancer-testis Specific Gene OIP5: A Downstream Gene of E2F1 that Promotes Tumorigenesis and Metastasis in Glioblastoma by Stabilizing E2F1 Signalling.
    Neuro Oncol. 2018 Mar 14. pii: 4934327. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. APPAY R, Tabouret E, Macagno N, Touat M, et al
    IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.
    Neuro Oncol. 2018 Mar 7. pii: 4924365. doi: 10.1093.
    PubMed     Text format    


  38. VANDERBEEK AM, Rahman R, Fell G, Ventz S, et al
    The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
    Neuro Oncol. 2018 Mar 6. pii: 4922286. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. COY S, Rashid R, Lin JR, Du Z, et al
    Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma.
    Neuro Oncol. 2018 Mar 2. pii: 4917565. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. BAGLEY SJ, Desai AS, Linette GP, June CH, et al
    CAR T Cell Therapy for Glioblastoma: Recent Clinical Advances and Future Challenges.
    Neuro Oncol. 2018 Mar 2. pii: 4917531. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  41. PARK JW, Wollmann G, Urbiola C, Fogli B, et al
    Sprouty2 enhances the tumorigenic potential of glioblastoma cells.
    Neuro Oncol. 2018 Feb 23. pii: 4904223. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. OSTROM QT, Rubin JB, Lathia JD, Berens ME, et al
    Females have the survival advantage in glioblastoma.
    Neuro Oncol. 2018 Feb 21. pii: 4883496. doi: 10.1093.
    PubMed     Text format    


  43. BLUMENTHAL DT, Won M, Mehta MP, Gilbert MR, et al
    Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group (RTOG) database.
    Neuro Oncol. 2018 Feb 15. pii: 4861801. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. BASKARAN S, Mayrhofer M, Kultima HG, Bergstrom T, et al
    Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages.
    Neuro Oncol. 2018 Feb 15. pii: 4860173. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. CHOI S, Yu Y, Grimmer MR, Wahl M, et al
    Temozolomide-associated Hypermutation in Gliomas.
    Neuro Oncol. 2018 Feb 14. pii: 4857168. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. ZHOU M, Zhou Y, Liao H, Rowland BC, et al
    Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.
    Neuro Oncol. 2018 Feb 9. pii: 4846845. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. ABOUNADER R
    A new practical and versatile mouse model of proneural glioblastoma.
    Neuro Oncol. 2018 Feb 8. pii: 4842815. doi: 10.1093.
    PubMed     Text format    


  48. ALDAPE K, Amin SB, Ashley DM, Barnholtz-Sloan JS, et al
    Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium.
    Neuro Oncol. 2018 Feb 8. pii: 4843984. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. LIAO P, Ostrom QT, Stetson L, Barnholtz-Sloan JS, et al
    Models of Epigenetic Age Capture Patterns of DNA Methylation in Glioma Associated with Molecular Subtype, Survival, and Recurrence.
    Neuro Oncol. 2018 Feb 8. pii: 4844022. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. BRENNER A, Zuniga R, Sun JD, Floyd J, et al
    Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I surgical study.
    Neuro Oncol. 2018 Feb 5. pii: 4838327. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. NHAT TRAN A, Walker K, Harrison DG, Chen W, et al
    Reactive Species Balance via GTP Cyclohydrolase I Regulates Glioblastoma Growth and Tumor Initiating Cell Maintenance.
    Neuro Oncol. 2018 Feb 2. pii: 4835145. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. LOUVRIER C, Pasmant E, Briand-Suleau A, Cohen J, et al
    Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Neuro Oncol. 2018 Feb 2. pii: 4835073. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. MONCAYO G, Grzmil M, Smirnova T, Zmarz P, et al
    SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
    Neuro Oncol. 2018 Feb 1. pii: 4833547. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  54. ALDAVE G, Gonzalez-Huarriz M, Rubio A, Romero JP, et al
    The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
    Neuro Oncol. 2018 Jan 24. pii: 4823831. doi: 10.1093.
    PubMed     Text format     Abstract available


  55. AUDIA A, Bhat KP
    Ritanserin, a novel agent targeting the mesenchymal subtype of glioblastomas.
    Neuro Oncol. 2018;20:151-152.
    PubMed     Text format    


  56. RUBIN JB, Finlay JL
    Pediatric low-grade gliomas: a brave new world.
    Neuro Oncol. 2018;20:149-150.
    PubMed     Text format    


  57. WARREN KE, Vezina G, Poussaint TY, Warmuth-Metz M, et al
    Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee".
    Neuro Oncol. 2018;20:144-145.
    PubMed     Text format    


  58. HARRELD JH
    Comment on "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee".
    Neuro Oncol. 2018;20:143-144.
    PubMed     Text format    


  59. PRUST ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, et al
    Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss.
    Neuro Oncol. 2018 Jan 5. pii: 4791799. doi: 10.1093.
    PubMed     Text format    


  60. CHIN AL, Moding EJ, Donaldson SS, Gibbs IC, et al
    Survival Impact of Postoperative Radiotherapy Timing in Pediatric and Adolescent Medulloblastoma.
    Neuro Oncol. 2018 Jan 4. pii: 4788577. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. RUDA R, Soffietti R
    Extent of surgery in low-grade gliomas: an old question in a new context.
    Neuro Oncol. 2018 Jan 3. pii: 4788257. doi: 10.1093.
    PubMed     Text format    


    December 2017
  62. PARK J, Shim JK, Kang JH, Choi J, et al
    Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.
    Neuro Oncol. 2017 Dec 23. pii: 4773887. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. MAHLOKOZERA T, Vellimana AK, Li T, Mao DD, et al
    Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas.
    Neuro Oncol. 2017 Dec 13. pii: 4737220. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. CALMON R, Puget S, Varlet P, Dangouloff-Ros V, et al
    Cerebral blood flow changes after radiation therapy identifies pseudo-progression in diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2017 Dec 13. pii: 4737113. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. IUS T, Ciani Y, Ruaro ME, Isola M, et al
    A NF-kappaB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
    Neuro Oncol. 2017 Dec 7. pii: 4708291. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. PEYRE M, Gauchotte G, Giry M, Froehlich S, et al
    De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Neuro Oncol. 2017 Dec 5. pii: 4694050. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  67. GUERRINI-ROUSSEAU L, Dufour C, Varlet P, Masliah-Planchon J, et al
    Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk and prognosis.
    Neuro Oncol. 2017 Nov 24. pii: 4657092. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. PFAFF E, Kessler T, Balasubramanian GP, Berberich A, et al
    Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation - the NCT Neuro Master Match (N2M2) pilot study.
    Neuro Oncol. 2017 Nov 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. DOVER LL, Dulaney CR, Williams CP, Fiveash JB, et al
    Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumors.
    Neuro Oncol. 2017 Nov 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. ABDELBAKI MS, Boue DR, Finlay JL, Kieran MW, et al
    Desmoplastic Nodular Medulloblastoma in Young Children: A Management Dilemma.
    Neuro Oncol. 2017 Nov 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. NASSIRI F, Zadeh G, Aldape K
    IDH mutation testing in gliomas-where do we draw the line?
    Neuro Oncol. 2017 Nov 11. doi: 10.1093.
    PubMed     Text format    


  72. LAKS DR, Oses-Prieto JA, Alvarado AG, Nakashima J, et al
    A Molecular Cascade Modulates MAP1B and Confers Resistance to mTOR Inhibition in Human Glioblastoma.
    Neuro Oncol. 2017 Nov 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. SCHAFER N, Proescholdt M, Steinbach JP, Weyerbrock A, et al
    Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
    Neuro Oncol. 2017 Nov 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. GONDI V, Mehta MP
    Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis.
    Neuro Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format    


  75. CHINNAIYAN P, Won M, Wen PY, Rojiani AM, et al
    A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.
    Neuro Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. CARAGHER SP, Hall RR 3rd, Ahsan R, Ahmed AU, et al
    Monoamines in Glioblastoma: complex biology with therapeutic potential.
    Neuro Oncol. 2017 Nov 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. WANG J, Yang ZY, Guo YF, Kuang JY, et al
    Targeting different domains of gap junction protein to control malignant glioma.
    Neuro Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  78. BANASAVADI-SIDDEGOWDA YK, Welker AM, An M, Yang X, et al
    PRMT5 as a druggable target for glioblastoma therapy.
    Neuro Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  79. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2017 Nov 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  80. DEUMELANDT K, Platten M, Ochs K
    Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.
    Neuro Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format    


  81. OMURO A, Vlahovic G, Lim M, Sahebjam S, et al
    Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.
    Neuro Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. GAN HK, Reardon DA, Lassman AB, Merrell R, et al
    Safety, Pharmacokinetics and Antitumor Response of Depatuxizumab Mafodotin as Monotherapy or in Combination with Temozolomide in Patients with Glioblastoma.
    Neuro Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  83. HAYES J, Yu Y, Jalbert LE, Mazor T, et al
    Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  84. PLATTEN M
    EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?
    Neuro Oncol. 2017;19:1425-1426.
    PubMed     Text format    


  85. UNTERRAINER M, Niyazi M, Ruf V, Bartenstein P, et al
    The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
    Neuro Oncol. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format    


  86. FORST D, Adams E, Nipp R, Martin A, et al
    Hospice Utilization in Patients with Malignant Gliomas.
    Neuro Oncol. 2017 Oct 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. ELLINGSON BM, Wen PY, Cloughesy TF
    Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.
    Neuro Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  88. ESKILSSON E, Rosland GV, Solecki G, Wang Q, et al
    EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
    Neuro Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. RUIZ VY, Praska CE, Armstrong G, Kollmeyer TM, et al
    Molecular Subtyping of Tumors from Patients with Familial Glioma.
    Neuro Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. CLOUGHESY TF, Drappatz J, de Groot J, Prados MD, et al
    Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
    Neuro Oncol. 2017 Oct 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. JOHN-PAUL K, Bartels U
    Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply.
    Neuro Oncol. 2017;19:1420-1421.
    PubMed     Text format    


  92. PENAS-PRADO M, de Groot J
    CATNON interim results: another triumph of upfront chemotherapy in glioma.
    Neuro Oncol. 2017;19:1287-1288.
    PubMed     Text format    


  93. CAVALHEIRO S
    Intracystic interferon-alpha in pediatric craniopharyngioma patients.
    Neuro Oncol. 2017;19:1419.
    PubMed     Text format    


  94. LOU E
    Can you hear them now? Tumor microtubes form cellular communication networks that protect gliomas from surgical lesions and chemotherapy treatments.
    Neuro Oncol. 2017;19:1289-1291.
    PubMed     Text format    


    September 2017
  95. KICKINGEREDER P, Neuberger U, Bonekamp D, Piechotta PL, et al
    Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma.
    Neuro Oncol. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. MALTA TM, de Souza CF, Sabedot TS, Silva TC, et al
    Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications.
    Neuro Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. KAUR S, Ramdzan ZM, Guiot MC, Li L, et al
    CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide.
    Neuro Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  98. SAHM F, Wick A
    ID(H)entifying checkpoint inhibitor candidates among diffuse glioma.
    Neuro Oncol. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format    


  99. BIELAMOWICZ K, Fousek K, Byrd TT, Samaha H, et al
    Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  100. HEFFRON TP
    Challenges of developing small molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  101. PRIDHAM KJ, Le L, Guo S, Varghese RT, et al
    PIK3CB/p110beta is a Selective Survival Factor for Glioblastoma.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. POETSCH N, Woehrer A, Gesperger J, Furtner J, et al
    Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for survival of newly diagnosed and treatment naive gliomas.
    Neuro Oncol. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  103. HARDY KK, Willard VW, Gioia A, Sharkey C, et al
    Attention-mediated neurocognitive profiles in survivors of pediatric brain tumors: Comparison to children with neurodevelopmental ADHD.
    Neuro Oncol. 2017 Sep 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  104. SARKARIA JN, Hu LS, Parney IF, Pafundi DH, et al
    Is the blood-brain barrier really disrupted in all glioblastomas? - A critical assessment of existing clinical data.
    Neuro Oncol. 2017 Sep 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. WIJNENGA MMJ, French PJ, Dubbink HJ, Dinjens WNM, et al
    The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological and molecular analysis.
    Neuro Oncol. 2017 Sep 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  106. SHIBAO S, Minami N, Koike N, Fukui N, et al
    Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model.
    Neuro Oncol. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. BALASUBRAMANIYAN V, Bhat KP
    Targeting MIR155HG in glioma: a novel approach.
    Neuro Oncol. 2017;19:1152-1153.
    PubMed     Text format    


  108. COONEY T, Lane A, Bartels U, Bouffet E, et al
    Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study.
    Neuro Oncol. 2017;19:1279-1280.
    PubMed     Text format    


  109. SCHNEIDER M, Reitter EM, Kastner MT, Thannesberger J, et al
    Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment.
    Neuro Oncol. 2017;19:1280-1282.
    PubMed     Text format    


  110. GOERIG NL, Frey B, Uberla K, Gaipl U, et al
    A clinician's plea to test glioma patients for CMV.
    Neuro Oncol. 2017;19:1282-1283.
    PubMed     Text format    


  111. NOWOSIELSKI M, Ellingson BM, Chinot OL, Garcia J, et al
    Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio.
    Neuro Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  112. ANDERSEN ZJ, Pedersen M, Weinmayr G, Stafoggia M, et al
    Long-term Exposure to Ambient Air Pollution and Incidence of Brain Tumor: the European Study of Cohorts for Air Pollution Effects (ESCAPE).
    Neuro Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  113. SZULZEWSKY F, Schwendinger N, Guneykaya D, Cimino PJ, et al
    Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.
    Neuro Oncol. 2017 Aug 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  114. TAUNK NK, Oh JH, Shukla-Dave A, Beal K, et al
    Early Post-treatment Assessment of MRI Perfusion Biomarkers Can Predict Long-term Response of Lung Cancer Brain Metastases to Stereotactic Radiosurgery.
    Neuro Oncol. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. KESSLER T, Sahm F, Sadik A, Stichel D, et al
    Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Neuro Oncol. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  116. KHAGI S, Miller CR
    Putting "multiforme" back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.
    Neuro Oncol. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format    


  117. GALANIS E, Anderson SK, Miller CR, Sarkaria JN, et al
    Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02.
    Neuro Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  118. DAGMAR D, Proescholdt M, Reinert C, Pietsch T, et al
    Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
    Neuro Oncol. 2017 Aug 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  119. WEN PY, Drappatz J, de Groot J, Prados MD, et al
    Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
    Neuro Oncol. 2017 Aug 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  120. LANG FM, Hossain A, Gumin J, Momin EN, et al
    Mesenchymal Stem Cells as Natural Bio-Factories for Exosomes Carrying miR-124a in the Treatment of Gliomas.
    Neuro Oncol. 2017 Aug 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  121. KARREMANN M, Gielen GH, Hoffmann M, Wiese M, et al
    Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Neuro Oncol. 2017 Aug 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  122. JONES DTW, Kieran MW, Bouffet E, Alexandrescu S, et al
    Pediatric Low-Grade Gliomas: Next Biologically Driven Steps.
    Neuro Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  123. GROSSMAN SA, Kleinberg L
    A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
    Neuro Oncol. 2017;19:1019-1020.
    PubMed     Text format    


    July 2017
  124. MANDEL JJ, Yust-Katz S, Patel AJ, Cachia D, et al
    Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.
    Neuro Oncol. 2017 Jul 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  125. GARNIER D, Meehan B, Kislinger T, Daniel P, et al
    Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Neuro Oncol. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  126. PHILIP J, Collins A, Brand C, Sundararajan V, et al
    A Proposed Framework of Supportive and Palliative Care for people with High Grade Glioma.
    Neuro Oncol. 2017 Jul 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  127. BHERE D, Tamura K, Wakimoto H, Choi SH, et al
    microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
    Neuro Oncol. 2017 Jul 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  128. SPERANZA MC, Passaro C, Ricklefs F, Kasai K, et al
    Preclinical investigation of gene-mediated cytotoxic immunotherapy and checkpoint blockade in glioblastoma.
    Neuro Oncol. 2017 Jul 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  129. LEVESLEY J, Steele L, Bruning-Richardson A, Davison A, et al
    Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
    Neuro Oncol. 2017 Jul 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  130. SCHREIBER JE, Palmer SL, Conklin HM, Mabbott DJ, et al
    Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study.
    Neuro Oncol. 2017 Jul 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  131. AOKI K, Nakamura H, Suzuki H, Matsuo K, et al
    Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Jul 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  132. WICK A, Kessler T, Elia AEH, Winkler F, et al
    Glioblastoma in the elderly: solid conclusions built on shifting sand?
    Neuro Oncol. 2017 Jul 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  133. SHAN X, Fan X, Liu X, Zhao Z, et al
    Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis.
    Neuro Oncol. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  134. COULDWELL WT, Cannon-Albright LA
    A description of familial clustering of meningiomas in the Utah population.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  135. WU S, Wang S, Gao F, Li L, et al
    Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  136. JAHAN N, Talat H, Curry WT
    Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  137. RAHME GJ, Luikart BW, Cheng C, Israel MA, et al
    A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  138. TIROSH I, Suva ML
    Dissecting human gliomas by single-cell RNA sequencing.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  139. OKADA H, Thorne SH
    Is the immune response a friend or foe for viral therapy of glioma?
    Neuro Oncol. 2017;19:882-883.
    PubMed     Text format    


  140. ZHANG Z, Chan AK, Ding X, Li Y, et al
    Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Neuro Oncol. 2017;19:1008-1010.
    PubMed     Text format    


    June 2017
  141. OLMEZ I, Love S, Xiao A, Manigat L, et al
    Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.
    Neuro Oncol. 2017 Jun 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  142. QIAN Y, Maruyama S, Kim H, Pollom EL, et al
    Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.
    Neuro Oncol. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  143. DEWITT JC, Jordan JT, Frosch MP, Samore WR, et al
    Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
    Neuro Oncol. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  144. JIN L, Ge H, Long Y, Yang C, et al
    CD70, a novel target of CAR-T-cell therapy for gliomas.
    Neuro Oncol. 2017 Jun 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  145. DIAMOND EL, Prigerson HG, Correa DC, Reiner A, et al
    Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma.
    Neuro Oncol. 2017 Jun 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  146. GUTMANN DH
    Caddyshack therapeutics: overcoming glioblastoma adaptation.
    Neuro Oncol. 2017 Jun 16. doi: 10.1093.
    PubMed     Text format    


  147. GALLDIKS N, Albert NL, Sommerauer M, Grosu AL, et al
    PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  148. WU J, Frady LN, Bash RE, Cohen SM, et al
    MerTK as a therapeutic target in glioblastoma.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  149. KIERAN MW, Chisholm J, Casanova M, Brandes AA, et al
    Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
    Neuro Oncol. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  150. MORROW AM, Morgan RM, Villano JL
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials-impact of psychogenic non-epileptic seizures.
    Neuro Oncol. 2017 Jun 6. doi: 10.1093.
    PubMed     Text format    


  151. WANG X, Holgado BL, Ramaswamy V, Mack S, et al
    "miR miR on the wall, who's the most malignant medulloblastoma miR of them all?"
    Neuro Oncol. 2017 Jun 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  152. ZHOU X, Xie S, Wu S, Qi Y, et al
    Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  153. SEPULVEDA-SANCHEZ JM, Vaz MA, Balana C, Gil-Gil M, et al
    Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  154. ABUDUMIJITI A, Chan AK, Shi Z, Li Y, et al
    Adult IDH Wild-type Lower-grade Gliomas Should Be Further Stratified.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  155. ZHU C, Kros JM, Cheng C, Mustafa D, et al
    The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  156. NABORS LB
    When less is better: care of the elderly with glioblastoma.
    Neuro Oncol. 2017 May 26. doi: 10.1093.
    PubMed     Text format    


  157. GLASS JO, Ogg RJ, Hyun JW, Harreld JH, et al
    Disrupted development and integrity of frontal white matter in patients treated for pediatric medulloblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  158. KESARWANI P, Kant S, Prabhu A, Chinnaiyan P, et al
    The interplay between metabolic remodeling and immune regulation in glioblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  159. PRABHU A, Kesarwani P, Kant S, Graham SF, et al
    Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  160. KIERAN MW
    Lessons learned from diffuse intrinsic pontine glioma: how a terrible disease forced us to think better.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed     Text format    


  161. JACKSON S, ElAli A, Virgintino D, Gilbert MR, et al
    Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  162. KARIMI S, Vyas MV, Gonen L, Tabasinejad R, et al
    Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  163. BERGHOFF AS, Kiesel B, Widhalm G, Wilhelm D, et al
    Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  164. NOWOSIELSKI M, Galldiks N, Iglseder S, Kickingereder P, et al
    Diagnostic Challenges in Meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  165. COLMAN H
    Toward more informative biomarker-based clinical trials in glioblastoma.
    Neuro Oncol. 2017 May 17. doi: 10.1093.
    PubMed     Text format    


  166. GROSSMANN P, Narayan V, Chang K, Rahman R, et al
    Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  167. KILDAY JP, Caldarelli M, Massimi L, Chen RH, et al
    Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  168. SHANKAR GM, Santagata S
    BAP1 mutations in high-grade meningioma: implications for patient care.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  169. SCHMIDT C, Schubert NA, Brabetz S, Mack N, et al
    Pre-clinical drug screen reveals topotecan, actinomycin D and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  170. YESILOZ U, Kirches E, Hartmann C, Scholz J, et al
    Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Neuro Oncol. 2017 May 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  171. SILGINER M, Nagy S, Happold C, Schneider H, et al
    Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.
    Neuro Oncol. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  172. NARLOCH JL, Farber SH, Sammons S, McSherry F, et al
    Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.
    Neuro Oncol. 2017 May 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  173. MASON W
    NANO, a practical scale for neurologic assessments in patients with brain tumors?
    Neuro Oncol. 2017;19:603-604.
    PubMed     Text format    


  174. GITTLEMAN H, Lim D, Kattan MW, Chakravarti A, et al
    An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Neuro Oncol. 2017;19:669-677.
    PubMed     Text format     Abstract available


  175. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2017;19:719-725.
    PubMed     Text format     Abstract available


  176. TERRIER LM, Bauchet L, Rigau V, Amelot A, et al
    Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.
    Neuro Oncol. 2017;19:678-688.
    PubMed     Text format     Abstract available


  177. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2017;19:660-668.
    PubMed     Text format     Abstract available


  178. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2017;19:636-647.
    PubMed     Text format     Abstract available


  179. NAYAK L, DeAngelis LM, Brandes AA, Peereboom DM, et al
    The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
    Neuro Oncol. 2017;19:625-635.
    PubMed     Text format     Abstract available


  180. ZHU C, Mustafa D, Zheng PP, van der Weiden M, et al
    Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.
    Neuro Oncol. 2017;19:648-659.
    PubMed     Text format     Abstract available


  181. KLINE CN, Joseph NM, Grenert JP, van Ziffle J, et al
    Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
    Neuro Oncol. 2017;19:699-709.
    PubMed     Text format     Abstract available


    April 2017
  182. FIGUEROA JM, Skog J, Akers J, Li H, et al
    Detection of wtEGFR Amplification and EGFRvIII Mutation in CSF-Derived Extracellular Vesicles of Glioblastoma Patients.
    Neuro Oncol. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  183. WARREN KE, Vezina G, Poussaint TY, Warmuth-Metz M, et al
    Response Assessment in Medulloblastoma and Leptomeningeal Seeding Tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee.
    Neuro Oncol. 2017 Apr 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  184. CAGNEY DN, Martin AM, Catalano PJ, Redig AJ, et al
    Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study.
    Neuro Oncol. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  185. BROKINKEL B, Hess K, Mawrin C
    Brain invasion in Meningiomas - Clinical considerations and impact of neuropathological evaluation: A systematic Review.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  186. WEIL S, Osswald M, Solecki G, Grosch J, et al
    Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  187. VITUCCI M, Irvin DM, McNeill RS, Schmid RS, et al
    Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.
    Neuro Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  188. MITCHELL LA, Lopez Espinoza F, Mendoza D, Kato Y, et al
    Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
    Neuro Oncol. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  189. THOMPSON EM, Keir ST, Venkatraman T, Lascola C, et al
    The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  190. LIN AL, DeAngelis LM
    Reappraising the 2016 WHO classification for diffuse glioma.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format    


  191. WEN PY, Jiang T, Schiff D
    How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.
    Neuro Oncol. 2017;19:459-460.
    PubMed     Text format    


  192. GROSSMAN SA, Schreck KC, Ballman K, Alexander B, et al
    Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2017;19:469-474.
    PubMed     Text format    


  193. GROSSHANS DR, Mohan R, Gondi V, Shih HA, et al
    The role of image-guided intensity modulated proton therapy in glioma.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  194. SAHGAL A, Ruschin M, Ma L, Verbakel W, et al
    Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  195. GRANBERG KJ, Annala M, Lehtinen B, Kesseli J, et al
    Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
    Neuro Oncol. 2017 Apr 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  196. CAO Y, Tseng CL, Balter JM, Teng F, et al
    MR-guided radiation therapy: transformative technology and its role in the central nervous system.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  197. KIRKPATRICK JP, Soltys SG, Lo SS, Beal K, et al
    The radiosurgery fractionation quandary: single fraction or hypofractionation?
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  198. CHAMBERLAIN M, Junck L, Brandsma D, Soffietti R, et al
    Leptomeningeal metastases: a RANO proposal for response criteria.
    Neuro Oncol. 2017;19:484-492.
    PubMed     Text format     Abstract available


  199. MYNAREK M, Pizer B, Dufour C, van Vuurden D, et al
    Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data.
    Neuro Oncol. 2017;19:576-585.
    PubMed     Text format     Abstract available


  200. BATCHELOR TT, Gerstner ER, Ye X, Desideri S, et al
    Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-beta tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Neuro Oncol. 2017;19:567-575.
    PubMed     Text format     Abstract available


  201. HARDCASTLE J, Mills L, Malo CS, Jin F, et al
    Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Neuro Oncol. 2017;19:493-502.
    PubMed     Text format     Abstract available


    March 2017
  202. AHMED KA, Berglund AE, Welsh EA, Naghavi AO, et al
    The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity.
    Neuro Oncol. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format    


  203. HUANG R
    Response assessment in high-grade glioma: tumor volume as endpoint.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format    


  204. FOULADI M, Pfister SM
    MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format    


  205. MCNEILL RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, et al
    Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  206. COHEN KJ, Jabado N, Grill J
    Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  207. BLUMENTHAL DT, Gorlia T, Gilbert MR, Kim MM, et al
    Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  208. WU X, Wang Y, Yu T, Nie E, et al
    Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  209. WANG C, Kaprealian TB, Suh JH, Kubicky CD, et al
    Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  210. HODGES TR, Ott M, Xiu J, Gatalica Z, et al
    Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  211. HOLDHOFF M, Ye X, Supko JG, Nabors LB, et al
    Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Neuro Oncol. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  212. LAWLER SE
    Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment.
    Neuro Oncol. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format    


  213. JEON MS, Dhillon HM, Agar MR
    Sleep disturbance of adults with a brain tumor and their family caregivers: a systematic review.
    Neuro Oncol. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  214. HU X, Martinez-Ledesma E, Zheng S, Kim H, et al
    Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  215. MEI X, Chen YS, Chen FR, Xi SY, et al
    Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  216. ALVAREZ-BRECKENRIDGE C, Brastianos PK
    SMO mutant olfactory groove meningiomas-the next in line for targeted therapy.
    Neuro Oncol. 2017;19:305-306.
    PubMed     Text format    


  217. JENKINSON MD, Santarius T, Zadeh G, Aldape KD, et al
    Atypical meningioma-is it time to standardize surgical sampling techniques?
    Neuro Oncol. 2017;19:453-454.
    PubMed     Text format    


  218. YANG W, Garzon-Muvdi T, Braileanu M, Porras JL, et al
    Primary intramedullary spinal cord lymphoma: a population-based study.
    Neuro Oncol. 2017;19:414-421.
    PubMed     Text format     Abstract available


  219. TABOURET E, Houillier C, Martin-Duverneuil N, Blonski M, et al
    Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
    Neuro Oncol. 2017;19:422-429.
    PubMed     Text format     Abstract available


  220. ALDAPE K, Nejad R, Louis DN, Zadeh G, et al
    Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community.
    Neuro Oncol. 2017;19:336-344.
    PubMed     Text format     Abstract available


  221. BENTLEY RT, Ahmed AU, Yanke AB, Cohen-Gadol AA, et al
    Dogs are man's best friend: in sickness and in health.
    Neuro Oncol. 2017;19:312-322.
    PubMed     Text format     Abstract available


    February 2017
  222. ARIF T, Kerlin Y, Nakdimon I, Benharroch D, et al
    VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  223. BANERJEE A, Jakacki RI, Onar-Thomas A, Wu S, et al
    A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  224. COTE DJ, Downer MK, Zoltick ES, Smith TR, et al
    ABO blood group and risk of glioma.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    


  225. ANDERSON JL, Muraleedharan R, Oatman N, Klotter A, et al
    The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  226. HUANG YT, Zhang Y, Wu Z, Michaud DS, et al
    Genotype-based gene signature of glioma risk.
    Neuro Oncol. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  227. VAN DEN BENT MJ, Weller M, Wen PY, Kros JM, et al
    A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
    Neuro Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  228. TANGUTURI SK, Trippa L, Ramkissoon SH, Pelton K, et al
    Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.
    Neuro Oncol. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  229. FREYSCHLAG CF, Kerschbaumer J, Thome C
    Comment on: Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Neuro Oncol. 2017 Feb 18. doi: 10.1093.
    PubMed     Text format    


  230. GAHRMANN R, van den Bent M, van der Holt B, Vernhout RM, et al
    Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  231. HEINZEL A, Muller D, Yekta-Michael SS, Ceccon G, et al
    O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  232. D'ALESSANDRIS QG, Biffoni M, Martini M, Runci D, et al
    The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  233. ABOU-EL-ARDAT K, Seifert M, Becker K, Eisenreich S, et al
    Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  234. MEYRONET D, Esteban-Mader M, Bonnet C, Joly MO, et al
    Characteristics of H3 K27M-mutant gliomas in adults.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  235. TEGLASI V, Reiniger L, Fabian K, Pipek O, et al
    Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  236. RUDA R, Soffietti R
    Controversies in management of low-grade gliomas in light of new data from clinical trials.
    Neuro Oncol. 2017;19:143-144.
    PubMed     Text format    


  237. RODDY E, Mueller S
    Response to "Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of paediatric brain tumors".
    Neuro Oncol. 2017;19:299-300.
    PubMed     Text format    


  238. PASSOS J, Nzwalo H, Marques J, Azevedo A, et al
    Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of pediatric brain tumors.
    Neuro Oncol. 2017;19:298-299.
    PubMed     Text format    


  239. SOFFIETTI R, Abacioglu U, Baumert B, Combs SE, et al
    Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).
    Neuro Oncol. 2017;19:162-174.
    PubMed     Text format     Abstract available


  240. CHANG S, Zhang P, Cairncross JG, Gilbert MR, et al
    Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
    Neuro Oncol. 2017;19:252-258.
    PubMed     Text format     Abstract available


  241. MIRANDA-FILHO A, Pineros M, Soerjomataram I, Deltour I, et al
    Cancers of the brain and CNS: global patterns and trends in incidence.
    Neuro Oncol. 2017;19:270-280.
    PubMed     Text format     Abstract available


    January 2017
  242. ZHOU H, Vallieres M, Bai HX, Su C, et al
    MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Jan 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  243. ANTONIOS JP, Soto H, Everson RG, Moughon D, et al
    Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Neuro Oncol. 2017 Jan 23. pii: now287. doi: 10.1093.
    PubMed     Text format     Abstract available


  244. RAMKISSOON SH, Bandopadhayay P, Hwang J, Ramkissoon LA, et al
    Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
    Neuro Oncol. 2017 Jan 19. pii: now294. doi: 10.1093.
    PubMed     Text format     Abstract available


  245. COLWELL N, Larion M, Giles AJ, Seldomridge AN, et al
    Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.
    Neuro Oncol. 2017 Jan 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  246. BERGHOFF AS, Wolpert F, Holland-Letz T, Koller R, et al
    Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.
    Neuro Oncol. 2017 Jan 17. pii: now290. doi: 10.1093.
    PubMed     Text format     Abstract available


  247. BOETTO J, Bielle F, Sanson M, Peyre M, et al
    SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Neuro Oncol. 2017 Jan 12. pii: now276. doi: 10.1093.
    PubMed     Text format     Abstract available


  248. AYUSO JM, Monge R, Martinez-Gonzalez A, Virumbrales-Munoz M, et al
    Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events.
    Neuro Oncol. 2017 Jan 6. pii: now230. doi: 10.1093.
    PubMed     Text format     Abstract available


  249. TENG J, Carla da Hora C, Kantar RS, Nakano I, et al
    Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Neuro Oncol. 2017 Jan 6. pii: now253. doi: 10.1093.
    PubMed     Text format     Abstract available


  250. CHAMBERLAIN MC, Baik CS, Gadi VK, Bhatia S, et al
    Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
    Neuro Oncol. 2017;19:i1-i24.
    PubMed     Text format     Abstract available


  251. BOWMAN RL, Wang Q, Carro A, Verhaak RG, et al
    GlioVis data portal for visualization and analysis of brain tumor expression datasets.
    Neuro Oncol. 2017;19:139-141.
    PubMed     Text format    


  252. GUPTA NK, Nolan A, Omuro A, Reid EG, et al
    Long-term survival in AIDS-related primary central nervous system lymphoma.
    Neuro Oncol. 2017;19:99-108.
    PubMed     Text format     Abstract available


  253. RALEIGH DR, Solomon DA, Lloyd SA, Lazar A, et al
    Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.
    Neuro Oncol. 2017;19:78-88.
    PubMed     Text format     Abstract available


    December 2016
  254. WIEDMANN MK, Brunborg C, Di Ieva A, Lindemann K, et al
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
    Neuro Oncol. 2016 Dec 31. pii: now272. doi: 10.1093.
    PubMed     Text format     Abstract available


  255. CICONE F, Galldiks N, Minniti G, Filss CP, et al
    Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury.
    Neuro Oncol. 2016 Dec 31. pii: now283. doi: 10.1093.
    PubMed     Text format    


  256. YOUNG RJ, Yang TJ, Hatzoglou V, Ulaner G, et al
    "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.
    Neuro Oncol. 2016 Dec 31. pii: now286. doi: 10.1093.
    PubMed     Text format    


  257. MARISETTY AL, Singh SK, Nguyen TN, Coarfa C, et al
    REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
    Neuro Oncol. 2016 Dec 31. pii: now232. doi: 10.1093.
    PubMed     Text format     Abstract available


  258. ROTH P, Valavanis A, Weller M
    Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
    Neuro Oncol. 2016 Dec 29. pii: now265. doi: 10.1093.
    PubMed     Text format    


  259. KING AA, Seidel K, Di C, Leisenring WM, et al
    Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study.
    Neuro Oncol. 2016 Dec 29. pii: now242. doi: 10.1093.
    PubMed     Text format     Abstract available


  260. REARDON DA, Lassman AB, van den Bent M, Kumthekar P, et al
    Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Neuro Oncol. 2016 Dec 29. pii: now257. doi: 10.1093.
    PubMed     Text format     Abstract available


  261. TSCHERPEL C, Dunkl V, Ceccon G, Stoffels G, et al
    The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Neuro Oncol. 2016 Dec 29. pii: now243. doi: 10.1093.
    PubMed     Text format     Abstract available


  262. ZHANG AS, Ostrom QT, Kruchko C, Rogers L, et al
    Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.
    Neuro Oncol. 2016 Dec 29. pii: now252. doi: 10.1093.
    PubMed     Text format     Abstract available


  263. ZAMANIPOOR NAJAFABADI AH, Peeters MC, Dirven L, Lobatto DJ, et al
    Impaired health-related quality of life in meningioma patients-a systematic review.
    Neuro Oncol. 2016 Dec 29. pii: now250. doi: 10.1093.
    PubMed     Text format     Abstract available


  264. TOONEN JA, Ma Y, Gutmann DH
    Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
    Neuro Oncol. 2016 Dec 29. pii: now267. doi: 10.1093.
    PubMed     Text format     Abstract available


  265. LIU TT, Achrol AS, Mitchell LA, Rodriguez SA, et al
    Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.
    Neuro Oncol. 2016 Dec 22. pii: now270. doi: 10.1093.
    PubMed     Text format     Abstract available


  266. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  267. LEE J, Hoxha E, Song HR
    A novel NFIA-NFkappaB feed-forward loop contributes to glioblastoma cell survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  268. PENG S, Dhurv H, Armstrong B, Salhia B, et al
    Integrated genomic analysis of survival outliers in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  269. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  270. KLEIN M
    Lesion momentum as explanation for preoperative neurocognitive function in patients with malignant glioma.
    Neuro Oncol. 2016;18:1595-1596.
    PubMed     Text format    


  271. SCHIFF D
    Molecular profiling optimizes the treatment of low-grade glioma.
    Neuro Oncol. 2016;18:1593-1594.
    PubMed     Text format    


    November 2016
  272. LASORELLA A, Sanson M, Iavarone A
    FGFR-TACC gene fusions in human glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  273. SHANKAR GM, Abedalthagafi M, Vaubel RA, Merrill PH, et al
    Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
    Neuro Oncol. 2016 Nov 9. doi: 10.1093.
    PubMed     Text format    


  274. ARMSTRONG FD
    Evidence of cerebral microbleeds and neurocognitive impairment following cranial radiation therapy for pediatric brain tumors: a new opportunity for improved care.
    Neuro Oncol. 2016;18:1470-1471.
    PubMed     Text format    


    October 2016
  275. YAGHI NK, Wei J, Hashimoto Y, Kong LY, et al
    Immune modulatory nanoparticle therapeutics for intracerebral glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  276. MENEI P, Clavreul A, Lemee JM
    Response To "Glioma Resection and Tumor Recurrence: Back To Semmelweis".
    Neuro Oncol. 2016.
    PubMed     Text format    


  277. RATEL D, van der Sanden B, Wion D
    Glioma resection and tumor recurrence: back to Semmelweis.
    Neuro Oncol. 2016.
    PubMed     Text format    


    September 2016
  278. PACKER RJ, Pfister S, Bouffet E, Avery R, et al
    Pediatric low-grade gliomas: implications of the biologic era.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  279. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  280. AVILA EK, Chamberlain M, Schiff D, Reijneveld JC, et al
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  281. WAGNER S, Lanfermann H, Eichner G, Gufler H, et al
    Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  282. PINHEIRO KV, Alves C, Buendia M, Gil MS, et al
    Targeting tyrosine receptor kinase B in gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  283. TALASILA KM, Rosland GV, Hagland HR, Eskilsson E, et al
    The angiogenic switch leads to a metabolic shift in human glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  284. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  285. KEBIR S, Rauschenbach L, Galldiks N, Schlaak M, et al
    Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  286. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016 Sep 2. doi: 10.1093.
    PubMed     Text format    


  287. BERENDSEN S, Snijders TJ, Robe PA
    Response to: "Prognostic relevance of epilepsy at presentation in lower-grade gliomas".
    Neuro Oncol. 2016;18:1327-8.
    PubMed     Text format    


  288. WATTS C, Langen KJ
    PET imaging in glioma: is it time for mainstream practice?
    Neuro Oncol. 2016;18:1193-4.
    PubMed     Text format    


    August 2016
  289. ELLINGSON BM, Harris RJ, Woodworth DC, Leu K, et al
    Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  290. TERRIER LM, Bauchet L, Rigau V, Amelot A, et al
    Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  291. NELSON SJ, Kadambi AK, Park I, Li Y, et al
    Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  292. GOMEZ-ROMAN N, Stevenson K, Gilmour L, Hamilton G, et al
    A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  293. WEFEL JS, Noll KR, Rao G, Cahill DP, et al
    Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  294. ROSENBERG S, Verreault M, Schmitt C, Guegan J, et al
    Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  295. KIM EH, Lee JH, Oh Y, Koh I, et al
    Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  296. WAHL M, Phillips JJ, Molinaro AM, Lin Y, et al
    Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  297. YANG R, Sarkar S, Korchinski DJ, Wu Y, et al
    MRI monitoring of monocytes to detect immune stimulating treatment response in brain tumor.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  298. MCTYRE ER, Johnson AG, Ruiz J, Isom S, et al
    Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  299. NGUYEN HN, Lie A, Li T, Chowdhury R, et al
    Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  300. RIGGS L, Piscione J, Laughlin S, Cunningham T, et al
    Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  301. RODDY E, Sear K, Felton E, Tamrazi B, et al
    Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  302. KANN BH, Lester-Coll NH, Park HS, Yeboa DN, et al
    Adjuvant chemotherapy and overall survival in adult medulloblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  303. BERGHOFF AS, Preusser M
    In search of a target: PD-1 and PD-L1 profiling across glioma types.
    Neuro Oncol. 2016.
    PubMed     Text format    


  304. VERMEULEN JF, van Hecke W, Jansen MK, Spliet WG, et al
    No evidence for human cytomegalovirus infection in pediatric medulloblastomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  305. WICK W, Chinot OL, Bendszus M, Mason W, et al
    Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  306. HU LS, Ning S, Eschbacher JM, Baxter LC, et al
    Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  307. PATEL P, Baradaran H, Delgado D, Askin G, et al
    MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  308. ARVOLD ND, Lee EQ, Mehta MP, Margolin K, et al
    Updates in the management of brain metastases.
    Neuro Oncol. 2016;18:1043-65.
    PubMed     Text format     Abstract available


    July 2016
  309. LI S, Zeng A, Hu Q, Yan W, et al
    miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  310. CECCON G, Lohmann P, Stoffels G, Judov N, et al
    Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  311. ZIEGLER J, Pody R, Coutinho de Souza P, Evans B, et al
    ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  312. LEHMAN NL, Hattab EM, Mobley BC, Usubalieva A, et al
    Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  313. JAFARI-KHOUZANI K, Loebel F, Bogner W, Rapalino O, et al
    Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  314. DUNET V, Prior JO
    Response to: Performance of 18F-FET-PET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics.
    Neuro Oncol. 2016;18:1029-30.
    PubMed     Text format    


  315. HUANG X, Bai H, Zhou H, Tang H, et al
    Performance of 18F-FET-PET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics.
    Neuro Oncol. 2016;18:1028.
    PubMed     Text format    


  316. LASSALETTA A, Ramaswamy V
    Medulloblastoma in adults: they're not just big kids.
    Neuro Oncol. 2016;18:895-7.
    PubMed     Text format    


  317. BARONE TA, Burkhart CA, Safina A, Haderski G, et al
    Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  318. GOFFART N, Lombard A, Lallemand F, Kroonen J, et al
    CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  319. HASHIZUME R, Zhang A, Mueller S, Prados MD, et al
    Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  320. WICK W, Roth P, Hartmann C, Hau P, et al
    Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  321. ZHOU H, Huang X, Bai HX, Tan X, et al
    Prognostic relevance of epilepsy at presentation in lower-grade gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


    June 2016
  322. LIN H, Patel S, Affleck VS, Wilson I, et al
    Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  323. ZHANG B, Chang K, Ramkissoon S, Tanguturi S, et al
    Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  324. BURTH S, Kickingereder P, Eidel O, Tichy D, et al
    Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  325. OKOLIE O, Bago JR, Schmid RS, Irvin DM, et al
    Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  326. VANNINI E, Olimpico F, Middei S, Ammassari-Teule M, et al
    Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  327. ARMSTRONG TS, Shade MY, Breton G, Gilbert MR, et al
    Sleep-wake disturbance in patients with brain tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  328. MANGANI D, Weller M, Seyed Sadr E, Willscher E, et al
    Limited role for transforming growth factor-beta pathway activation-mediated escape from VEGF inhibition in murine glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  329. ESKILSSON E, Rosland GV, Talasila KM, Knappskog S, et al
    EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  330. JONES C, Karajannis MA, Jones DT, Kieran MW, et al
    Pediatric high-grade glioma: biologically and clinically in need of new thinking.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  331. SCHIFF D
    PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity.
    Neuro Oncol. 2016;18:755-6.
    PubMed     Text format    


    May 2016
  332. ESKILSSON E, Verhaak RG
    Longitudinal genomic characterization of brain tumors for identification of therapeutic vulnerabilities.
    Neuro Oncol. 2016.
    PubMed     Text format    


  333. FOUNTAIN DM, Allen D, Joannides AJ, Nandi D, et al
    Reporting of patient-reported health-related quality of life in adults with diffuse low-grade glioma: a systematic review.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  334. GUHASARKAR D, Su Q, Gao G, Sena-Esteves M, et al
    Systemic AAV9-IFNbeta gene delivery treats highly invasive glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  335. LEBLANC AK, Mazcko C, Brown DE, Koehler JW, et al
    Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  336. BERNARD-ARNOUX F, Lamure M, Ducray F, Aulagner G, et al
    The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  337. YAGIZ K, Huang TT, Lopez Espinoza F, Mendoza D, et al
    Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  338. NAGASHIMA H, Tanaka K, Sasayama T, Irino Y, et al
    Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  339. CHANG K, Zhang B, Guo X, Zong M, et al
    Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  340. DE FEYTER HM, Behar KL, Rao JU, Madden-Hennessey K, et al
    A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  341. ZADEH G, Karimi S, Aldape KD
    PIK3CA mutations in meningioma.
    Neuro Oncol. 2016;18:603-4.
    PubMed     Text format    


    April 2016
  342. LAKS DR, Crisman TJ, Shih MY, Mottahedeh J, et al
    Large-scale assessment of the gliomasphere model system.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  343. ZHANG X, Rao A, Sette P, Deibert C, et al
    IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  344. LEDUR PF, Liu C, He H, Harris AR, et al
    Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  345. ZHAO F, Ohgaki H, Xu L, Giangaspero F, et al
    Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  346. MCDONALD CR, Delfanti RL, Krishnan AP, Leyden KM, et al
    Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  347. ALBERT NL, Weller M, Suchorska B, Galldiks N, et al
    Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  348. SEYSTAHL K, Stoecklein V, Schuller U, Rushing E, et al
    Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  349. CORREA DD, Satagopan J, Cheung K, Arora AK, et al
    COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  350. GRANT R, Brown PD
    Fatigue randomized controlled trials-how tired is "too tired" in patients undergoing glioma treatment?
    Neuro Oncol. 2016.
    PubMed     Text format    


  351. PATIL SS, Gokulnath P, Bashir M, Shwetha SD, et al
    Insulin-like growth factor binding protein-2 regulates beta-catenin signaling pathway in glioma cells and together contributes to poor patient prognosis.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  352. LEE HJ, Hanibuchi M, Kim SJ, Yu H, et al
    Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.
    Neuro Oncol. 2016;18:486-96.
    PubMed     Text format     Abstract available


  353. OSSWALD M, Solecki G, Wick W, Winkler F, et al
    A malignant cellular network in gliomas: potential clinical implications.
    Neuro Oncol. 2016;18:479-85.
    PubMed     Text format     Abstract available


    March 2016
  354. COOK PJ, Thomas R, Kingsley PJ, Shimizu F, et al
    Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  355. LULLA RR, Goldman S, Yamada T, Beattie CW, et al
    Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  356. SZABO E, Schneider H, Seystahl K, Rushing EJ, et al
    Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  357. CHINOT OL, Nishikawa R, Mason W, Henriksson R, et al
    Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  358. YUE X, Cao D, Lan F, Pan Q, et al
    MiR-301a is activated by the Wnt/beta-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  359. JAKACKI RI, Cohen KJ, Buxton A, Krailo MD, et al
    Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  360. GIELEN PR, Schulte BM, Kers-Rebel ED, Verrijp K, et al
    Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  361. CORDOVA JS, Shu HG, Liang Z, Gurbani SS, et al
    Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  362. POLLACK IF, Jakacki RI, Butterfield LH, Hamilton RL, et al
    Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomasdagger.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  363. PIAO Y, Park SY, Henry V, Smith BD, et al
    Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  364. PISKLAKOVA A, McKenzie B, Zemp F, Lun X, et al
    M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  365. YANG P, Cai J, Yan W, Zhang W, et al
    Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  366. XIPELL E, Aragon T, Martinez-Velez N, Vera B, et al
    Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  367. OSTERBERG N, Ferrara N, Vacher J, Gaedicke S, et al
    Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  368. NIGIM F, Esaki SI, Hood M, Lelic N, et al
    A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  369. BRANDES AA, Finocchiaro G, Zagonel V, Reni M, et al
    AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  370. PUROW B
    For glioma, a sweet side to diabetes.
    Neuro Oncol. 2016;18:306-7.
    PubMed     Text format    


  371. HELFER JL, Wen PY, Blakeley J, Gilbert MR, et al
    Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
    Neuro Oncol. 2016;18 Suppl 2:ii26-ii36.
    PubMed     Text format     Abstract available


  372. BLAKELEY JO, Coons SJ, Corboy JR, Leidy NK, et al
    Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.
    Neuro Oncol. 2016;18 Suppl 2:ii13-ii20.
    PubMed     Text format     Abstract available


  373. ARMSTRONG TS, Bishof AM, Brown PD, Klein M, et al
    Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.
    Neuro Oncol. 2016;18 Suppl 2:ii1-ii12.
    PubMed     Text format     Abstract available


  374. BALLESTER LY, Olar A, Roy-Chowdhuri S
    Next-generation sequencing of central nervous systems tumors: the future of personalized patient management.
    Neuro Oncol. 2016;18:308-10.
    PubMed     Text format    


    February 2016
  375. KATHAGEN-BUHMANN A, Schulte A, Weller J, Holz M, et al
    Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  376. SHOJI T, Saito R, Chonan M, Shibahara I, et al
    Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  377. JALBERT LE, Neill E, Phillips JJ, Lupo JM, et al
    Magnetic resonance analysis of malignant transformation in recurrent glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  378. STELLA GM, Senetta R, Inghilleri S, Verdun di Cantogno L, et al
    MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer.
    Neuro Oncol. 2016.
    PubMed     Text format    


  379. BRANDES AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, et al
    A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  380. LEE EQ, Muzikansky A, Drappatz J, Kesari S, et al
    A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  381. KLINE CN, Joseph NM, Grenert JP, van Ziffle J, et al
    Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  382. VOGELBAUM MA
    The benefit of surgical resection in recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format    


  383. SOMMERAUER M, Burkhardt JK, Frontzek K, Rushing E, et al
    68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  384. WHEELER LA, Manzanera AG, Bell SD, Cavaliere R, et al
    Phase 2 multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  385. FRANCESCHI S, Lessi F, Aretini P, Mazzanti CM, et al
    Molecular portrait of a rare case of metastatic glioblastoma: somatic and germline mutations using whole-exome sequencing.
    Neuro Oncol. 2016;18:298-300.
    PubMed     Text format    


  386. KESSLER T
    Predicting glioblastoma response to bevacizumab through marker profiling?
    Neuro Oncol. 2016;18:149-50.
    PubMed     Text format    


  387. ALEXANDER BM
    Radiation de-intensification for patients with glioblastoma and poor prognostic features-how much do we really know?
    Neuro Oncol. 2016;18:147-8.
    PubMed     Text format    


  388. BAUMGARTEN P, Blank AE, Franz K, Hattingen E, et al
    Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Neuro Oncol. 2016;18:173-83.
    PubMed     Text format     Abstract available


  389. RUDA R, Bosa C, Magistrello M, Franchino F, et al
    Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
    Neuro Oncol. 2016;18:261-8.
    PubMed     Text format     Abstract available


    January 2016
  390. KERBEL RS
    Exploiting drug repositioning and the brain microenvironment to treat brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  391. SCHMID RS, Simon JM, Vitucci M, McNeill RS, et al
    Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  392. ABEDALTHAGAFI M, Bi WL, Aizer AA, Merrill PH, et al
    Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  393. SUCHORSKA B, Weller M, Tabatabai G, Senft C, et al
    Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  394. ALKINS R, Burgess A, Kerbel R, Wels WS, et al
    Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  395. SARAN F, Chinot OL, Henriksson R, Mason W, et al
    Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  396. KIM MM, Parmar H, Cao Y, Knox SJ, et al
    Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  397. THORNE AH, Zanca C, Furnari F
    Epidermal growth factor receptor targeting and challenges in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  398. SANCHEZ-OSUNA M, Martinez-Escardo L, Granados-Colomina C, Martinez-Soler F, et al
    An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  399. SOFFIETTI R, Ruda R, Trakul N, Chang EL, et al
    Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?
    Neuro Oncol. 2016;18:12-5.
    PubMed     Text format    


  400. OSTROM QT, Gittleman H, de Blank PM, Finlay JL, et al
    American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.
    Neuro Oncol. 2016;18 Suppl 1:i1-i50.
    PubMed     Text format    


  401. SCHIFF D
    Quantifying the burden of primary central nervous system malignancy.
    Neuro Oncol. 2016;18:5-6.
    PubMed     Text format    


  402. ROUSE C, Gittleman H, Ostrom QT, Kruchko C, et al
    Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.
    Neuro Oncol. 2016;18:70-7.
    PubMed     Text format     Abstract available


  403. LEE JK, Chang N, Yoon Y, Yang H, et al
    USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.
    Neuro Oncol. 2016;18:37-47.
    PubMed     Text format     Abstract available


    December 2015
  404. DE LA FUENTE MI, Young RJ, Rubel J, Rosenblum M, et al
    Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  405. HATZOGLOU V, Yang TJ, Omuro A, Gavrilovic I, et al
    A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  406. EATON BR, Esiashvili N, Kim S, Patterson B, et al
    Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  407. WIRSCHING HG, Morel C, Gmur C, Neidert MC, et al
    Predicting outcome of epilepsy after meningioma resection.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  408. HOVER LD, Owens P, Munden AL, Wang J, et al
    Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  409. XU Z, Zeng X, Xu J, Xu D, et al
    Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  410. DI K, Lloyd GK, Abraham V, MacLaren A, et al
    Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  411. WEI J, Nduom EK, Kong LY, Hashimoto Y, et al
    MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  412. MOLINARO AM, Wrensch MR, Jenkins RB, Eckel-Passow JE, et al
    Statistical considerations on prognostic models for glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  413. HWANG WL, Marciscano AE, Niemierko A, Kim DW, et al
    Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  414. XUAN F, Huang M, Liu W, Ding H, et al
    Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  415. DUBINSKI D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, et al
    CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  416. ROELCKE U, Wyss MT, Nowosielski M, Ruda R, et al
    Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  417. STAFFORD JH, Hirai T, Deng L, Chernikova SB, et al
    Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  418. ZHANG M, Gulotta B, Thomas A, Kaley T, et al
    Large-volume low lesion predicts poor survival in bevacizumab-treated glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  419. CAHILL KE, Morshed RA, Yamini B
    Nuclear factor-kappaB in glioblastoma: insights into regulators and targeted therapy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  420. ARMSTRONG TS, Grant R, Gilbert MR, Lee JW, et al
    Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available



  421. A new clinical guideline from the Royal College of Paediatrics and Child Health with a national awareness campaign accelerates brain tumor diagnosis in UK children-"HeadSmart: Be Brain Tumour Aware".
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  422. NDUOM EK, Weller M, Heimberger AB
    Immunosuppressive mechanisms in glioblastoma.
    Neuro Oncol. 2015;17 Suppl 7:vii9-vii14.
    PubMed     Text format     Abstract available


    October 2015
  423. LIU X, Madhankumar AB, Miller PA, Duck KA, et al
    MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  424. TAKANO K, Kinoshita M, Takagaki M, Sakai M, et al
    Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  425. ROGERS CL, Perry A, Pugh S, Vogelbaum MA, et al
    Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  426. POUSSAINT TY, Vajapeyam S, Ricci KI, Panigrahy A, et al
    Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  427. JASSAM SA, Maherally Z, Smith JR, Ashkan K, et al
    TNF-alpha enhancement of CD62E mediates adhesion of non-small cell lung cancer cells to brain endothelium via CD15 in lung-brain metastasis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  428. WICK W, Platten M, Wick A, Hertenstein A, et al
    Current status and future directions of anti-angiogenic therapy for gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  429. VELDHUIJZEN VAN ZANTEN SE, van Meerwijk CL, Jansen MH, Twisk JW, et al
    Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  430. BUTOWSKI N, Colman H, De Groot JF, Omuro AM, et al
    Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  431. VAN DER VOS KE, Abels ER, Zhang X, Lai C, et al
    Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  432. NOLL KR, Wefel JS
    Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function".
    Neuro Oncol. 2015;17:1421-2.
    PubMed     Text format    


  433. KANE JR
    From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function.
    Neuro Oncol. 2015;17:1420-1.
    PubMed     Text format    


  434. MANSOURI S, Zadeh G
    Neddylation in glioblastomas.
    Neuro Oncol. 2015;17:1305-6.
    PubMed     Text format    


    September 2015
  435. WALBERT T, Pace A
    End-of-life care in patients with primary malignant brain tumors: early is better.
    Neuro Oncol. 2015.
    PubMed     Text format    


  436. JONES KA, Gilder AS, Lam MS, Du N, et al
    Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  437. BERENDSEN S, Varkila M, Kroonen J, Seute T, et al
    Prognostic relevance of epilepsy at presentation in glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  438. HOU L, Jiang J, Liu B, Han W, et al
    Smoking and adult glioma: a population-based case-control study in China.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  439. COCKLE JV, Rajani K, Zaidi S, Kottke T, et al
    Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  440. WANG K, Wang Y, Fan X, Wang J, et al
    Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  441. MORANA G, Piccardo A, Puntoni M, Nozza P, et al
    Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  442. HABETS EJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, et al
    Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  443. HELLWINKEL JE, Redzic JS, Harland TA, Gunaydin D, et al
    Glioma-derived extracellular vesicles selectively suppress immune responses.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  444. HEGI ME, Stupp R
    Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma?
    Neuro Oncol. 2015.
    PubMed     Text format    


  445. ALVARADO AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, et al
    Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  446. SHIROISHI MS, Boxerman JL, Pope WB
    Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  447. FILBIN MG, Segal RA
    How neuronal activity regulates glioma cell proliferation.
    Neuro Oncol. 2015.
    PubMed     Text format    


  448. OBEROI RK, Parrish KE, Sio TT, Mittapalli RK, et al
    Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  449. KOCAKAYA S, Beier CP, Beier D
    Chemotherapy increases long-term survival in patients with adult medulloblastoma-a literature-based meta-analysis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  450. FURTNER J, Schopf V, Seystahl K, Le Rhun E, et al
    Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  451. DUBBINK HJ, Atmodimedjo PN, Kros JM, French PJ, et al
    Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  452. BERTOLINI F, Pecchi A, Stefani A, Fontana A, et al
    Everolimus effectively blocks pulmonary metastases from meningioma.
    Neuro Oncol. 2015;17:1301-2.
    PubMed     Text format    


  453. SUL J, Krainak DM
    Brain tumor clinical trials imaging: a (well-standardized) picture is worth a thousand words.
    Neuro Oncol. 2015;17:1179-80.
    PubMed     Text format    


  454. EVERSON RG, Antonios JP, Lisiero DN, Soto H, et al
    Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  455. NDUOM EK, Wei J, Yaghi NK, Huang N, et al
    PD-L1 expression and prognostic impact in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  456. AIZER AA, Abedalthagafi M, Linda Bi W, Horvath MC, et al
    A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  457. XIA S, Lal B, Tung B, Wang S, et al
    Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  458. ARMSTRONG TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, et al
    The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment-related symptoms.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available



  459. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
    Neuro Oncol. 2015.
    PubMed     Text format    


  460. DIAMOND EL, Russell D, Kryza-Lacombe M, Bowles KH, et al
    Rates and risks for late referral to hospice in patients with primary malignant brain tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  461. ZHU Y, Zhao K, Prinz A, Keyvani K, et al
    Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  462. BLUML S, Margol AS, Sposto R, Kennedy RJ, et al
    Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  463. ELLINGSON BM, Bendszus M, Boxerman J, Barboriak D, et al
    Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  464. DAVIS B, Shen Y, Poon CC, Luchman HA, et al
    Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  465. TOGAO O, Hiwatashi A, Yamashita K, Kikuchi K, et al
    Differentiation of high-grade and low-grade diffuse gliomas by intravoxel incoherent motion MR imaging.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  466. DUNET V, Pomoni A, Hottinger A, Nicod-Lalonde M, et al
    Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  467. RINGEL F, Pape H, Sabel M, Krex D, et al
    Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  468. TABOURET E, Boudouresque F, Farina P, Barrie M, et al
    MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.
    Neuro Oncol. 2015;17:1174-6.
    PubMed     Text format    


  469. NOWAK J, Seidel C, Pietsch T, Alkonyi B, et al
    Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified.
    Neuro Oncol. 2015;17:1157-65.
    PubMed     Text format     Abstract available


  470. POPE WB
    Predictive imaging marker of bevacizumab efficacy: perfusion MRI.
    Neuro Oncol. 2015;17:1046-7.
    PubMed     Text format    


    July 2015
  471. LUPO JM, Molinaro AM, Essock-Burns E, Butowski N, et al
    The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with gliomadagger.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  472. WALKER PR, Migliorini D
    The CD40/CD40L axis in glioma progression and therapy.
    Neuro Oncol. 2015.
    PubMed     Text format    


  473. LEMEE JM, Clavreul A, Menei P
    Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  474. WANGARYATTAWANICH P, Hatami M, Wang J, Thomas G, et al
    Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  475. PALLUD J, Audureau E, Noel G, Corns R, et al
    Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  476. FRIEDMAN GK, Moore BP, Nan L, Kelly VM, et al
    Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  477. MACYSZYN L, Akbari H, Pisapia JM, Da X, et al
    Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  478. WAITKUS MS, Diplas BH, Yan H
    Isocitrate dehydrogenase mutations in gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  479. HARSHYNE LA, Nasca BJ, Kenyon LC, Andrews DW, et al
    Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  480. OUYANG Q, Chen G, Zhou J, Li L, et al
    Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  481. AGNIHOTRI S, Zadeh G
    Metabolic reprogramming in glioblastoma: The influence of cancer metabolism on epigenetics and unanswered questions.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  482. BADVE C, Sloan AE
    Modeling the growth dynamics of glioblastoma using magnetic resonance imaging.
    Neuro Oncol. 2015.
    PubMed     Text format    


  483. COBBS C
    Reply to: Towards an unbiased, collaborative effort to reach evidence about the presence of human cytomegalovirus in glioblastoma (and other tumors).
    Neuro Oncol. 2015;17:1040.
    PubMed     Text format    


  484. MICHAELIS M, Mittelbronn M, Cinatl J Jr
    Towards an unbiased, collaborative effort to reach evidence about the presence of human cytomegalovirus in glioblastoma (and other tumors).
    Neuro Oncol. 2015;17:1039.
    PubMed     Text format    


  485. MEHTA MP
    The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients.
    Neuro Oncol. 2015;17:919-23.
    PubMed     Text format    


  486. SAHGAL A
    Point/Counterpoint: Stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain metastases: the current standard of care?
    Neuro Oncol. 2015;17:916-8.
    PubMed     Text format    


  487. WEN PY
    Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases.
    Neuro Oncol. 2015;17:915.
    PubMed     Text format    


  488. GUNN ME, Malila N, Lahdesmaki T, Arola M, et al
    Late new morbidity in survivors of adolescent and young-adulthood brain tumors in Finland: a registry-based study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  489. GONG Y, Ma Y, Sinyuk M, Loganathan S, et al
    Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  490. MASON WP
    Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  491. KREHER S, Johrens K, Strehlow F, Martus P, et al
    Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
    Neuro Oncol. 2015;17:1016-21.
    PubMed     Text format     Abstract available


    June 2015
  492. FIELD KM, Simes J, Nowak AK, Cher L, et al
    Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  493. GALLDIKS N, Langen KJ, Pope WB
    From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  494. ABHINAV K, Yeh FC, Mansouri A, Zadeh G, et al
    High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  495. HARRIS RJ, Cloughesy TF, Liau LM, Prins RM, et al
    pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  496. ACQUAYE AA, Lin L, Vera-Bolanos E, Gilbert MR, et al
    Hope and mood changes throughout the primary brain tumor illness trajectory.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  497. FEICHTINGER RG, Weis S, Mayr JA, Zimmermann FA, et al
    Alterations of oxidative phosphorylation in meningiomas and peripheral nerve sheath tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  498. SELIGER C, Ricci C, Meier CR, Bodmer M, et al
    Diabetes, use of antidiabetic drugs, and the risk of glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  499. BOSNYAK E, Kamson DO, Guastella AR, Varadarajan K, et al
    Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  500. BADHIWALA JH, Almenawer SA
    Extent of surgical resection of high-grade glioma among the elderly.
    Neuro Oncol. 2015;17:903-4.
    PubMed     Text format    


    May 2015
  501. WEN PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, et al
    Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  502. WALSH KM, Wiencke JK, Lachance DH, Wiemels JL, et al
    Telomere maintenance and the etiology of adult glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  503. PATEL KR, Lawson DH, Kudchadkar RR, Carthon BC, et al
    Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  504. ZHOU Y, Wu S, Liang C, Lin Y, et al
    Transcriptional upregulation of microtubule-associated protein 2 is involved in the protein kinase A-induced decrease in the invasiveness of glioma cells.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  505. GALLDIKS N, Stoffels G, Filss C, Rapp M, et al
    The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  506. CHONAN M, Saito R, Shoji T, Shibahara I, et al
    CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  507. GERSTNER ER, Ye X, Duda DG, Levine MA, et al
    A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  508. KSHETTRY VR, Ostrom QT, Kruchko C, Al-Mefty O, et al
    Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  509. NICLOU SP
    Gauging heterogeneity in primary versus recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  510. BECKER CM, Oberoi RK, McFarren SJ, Muldoon DM, et al
    Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  511. LIM M
    Immunotherapy for glioblastoma: are we finally getting closer?
    Neuro Oncol. 2015.
    PubMed     Text format    


  512. SCHIFF D, Sarkaria J
    Dasatinib in recurrent glioblastoma: failure as a teacher.
    Neuro Oncol. 2015.
    PubMed     Text format    


  513. VLAHOVIC G, Fecci PE, Reardon D, Sampson JH, et al
    Programmed death-ligand 1(PD-L1) as an immunotherapy target in patients with glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  514. ACHARYA S, DeWees T, Shinohara ET, Perkins SM, et al
    Long-term outcomes and late effects for childhood and young adulthood intracranial germinomas.
    Neuro Oncol. 2015;17:741-6.
    PubMed     Text format     Abstract available


  515. MUNCH TN, Gortz S, Wohlfahrt J, Melbye M, et al
    The long-term risk of malignant astrocytic tumors after structural brain injury--a nationwide cohort study.
    Neuro Oncol. 2015;17:718-24.
    PubMed     Text format     Abstract available


  516. LEE J, Dang X, Borboa A, Coimbra R, et al
    Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation.
    Neuro Oncol. 2015;17:685-96.
    PubMed     Text format     Abstract available


  517. HORNQUIST L, Rickardsson J, Lannering B, Gustafsson G, et al
    Altered self-perception in adult survivors treated for a CNS tumor in childhood or adolescence: population-based outcomes compared with the general population.
    Neuro Oncol. 2015;17:733-40.
    PubMed     Text format     Abstract available


    April 2015
  518. AVULA S, Kumar R, Pizer B, Pettorini B, et al
    Diffusion abnormalities on intraoperative magnetic resonance imaging as an early predictor for the risk of posterior fossa syndrome.
    Neuro Oncol. 2015;17:614-22.
    PubMed     Text format     Abstract available


  519. CHAKRAVADHANULA M, Hampton CN, Chodavadia P, Ozols V, et al
    Wnt pathway in atypical teratoid rhabdoid tumors.
    Neuro Oncol. 2015;17:526-35.
    PubMed     Text format     Abstract available


  520. GAO Y, Whitaker-Dowling P, Barmada MA, Basse PH, et al
    Viral infection of implanted meningeal tumors induces antitumor memory T-cells to travel to the brain and eliminate established tumors.
    Neuro Oncol. 2015;17:536-44.
    PubMed     Text format     Abstract available


    March 2015
  521. ZADEH G, Khan OH, Vogelbaum M, Schiff D, et al
    Much debated controversies of diffuse low-grade gliomas.
    Neuro Oncol. 2015;17:323-6.
    PubMed     Text format    


  522. ZACH L, Guez D, Last D, Daniels D, et al
    Delayed contrast extravasation MRI: a new paradigm in neuro-oncology.
    Neuro Oncol. 2015;17:457-65.
    PubMed     Text format     Abstract available


  523. TSUI K, Gajjar A, Li C, Srivastava D, et al
    Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy.
    Neuro Oncol. 2015;17:448-56.
    PubMed     Text format     Abstract available


  524. ZHI F, Shao N, Wang R, Deng D, et al
    Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma.
    Neuro Oncol. 2015;17:383-91.
    PubMed     Text format     Abstract available


  525. VERA-BOLANOS E, Aldape K, Yuan Y, Wu J, et al
    Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.
    Neuro Oncol. 2015;17:440-7.
    PubMed     Text format     Abstract available


    February 2015
  526. IWAMOTO FM, Lassman AB
    Factorial clinical trials: a new approach to phase II neuro-oncology studies.
    Neuro Oncol. 2015;17:174-6.
    PubMed     Text format    


  527. ALEXANDER BM, Galanis E, Yung WK, Ballman KV, et al
    Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.
    Neuro Oncol. 2015;17:180-8.
    PubMed     Text format     Abstract available


  528. PACHOW D, Wick W, Gutmann DH, Mawrin C, et al
    The mTOR signaling pathway as a treatment target for intracranial neoplasms.
    Neuro Oncol. 2015;17:189-99.
    PubMed     Text format     Abstract available


    January 2015
  529. OSTROM QT, de Blank PM, Kruchko C, Petersen CM, et al
    Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.
    Neuro Oncol. 2015;16 Suppl 10:x1-x36.
    PubMed     Text format     Abstract available


  530. MCNEILL RS, Vitucci M, Wu J, Miller CR, et al
    Contemporary murine models in preclinical astrocytoma drug development.
    Neuro Oncol. 2015;17:12-28.
    PubMed     Text format     Abstract available


  531. LEE JS, Park JR, Kwon OS, Lee TH, et al
    SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner.
    Neuro Oncol. 2015;17:95-106.
    PubMed     Text format     Abstract available


  532. WANG J, Pulido JS, O'Neill BP, Johnston PB, et al
    Second malignancies in patients with primary central nervous system lymphoma.
    Neuro Oncol. 2015;17:129-35.
    PubMed     Text format     Abstract available


    September 2014
  533. PALLUD J, Duffau H
    Is a prospective trial necessary to suggest a clinical relevance?
    Neuro Oncol. 2014;16:1295-6.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: